MDT

87.93

+1.17%↑

VEEV

281.03

-0.66%↓

A

119.21

+0.2%↑

HQY

103.63

-1.89%↓

PHR.US

28.29

+0.07%↑

MDT

87.93

+1.17%↑

VEEV

281.03

-0.66%↓

A

119.21

+0.2%↑

HQY

103.63

-1.89%↓

PHR.US

28.29

+0.07%↑

MDT

87.93

+1.17%↑

VEEV

281.03

-0.66%↓

A

119.21

+0.2%↑

HQY

103.63

-1.89%↓

PHR.US

28.29

+0.07%↑

MDT

87.93

+1.17%↑

VEEV

281.03

-0.66%↓

A

119.21

+0.2%↑

HQY

103.63

-1.89%↓

PHR.US

28.29

+0.07%↑

MDT

87.93

+1.17%↑

VEEV

281.03

-0.66%↓

A

119.21

+0.2%↑

HQY

103.63

-1.89%↓

PHR.US

28.29

+0.07%↑

Erasca Inc

Отворен

1.28

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.22

Максимум

1.29

Ключови измерители

By Trading Economics

Приходи

1.3M

-31M

EPS

-0.11

Служители

103

EBITDA

-750K

-36M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+224.43% upside

Дивиденти

By Dow Jones

Следващи печалби

8.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

394M

Предишно отваряне

1.28

Предишно затваряне

1.28

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Erasca Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

30.06.2025 г., 21:26 ч. UTC

Значими двигатели на пазара

AeroVironment Shares Slide on Stock, Notes Offerings

30.06.2025 г., 16:50 ч. UTC

Придобивния, сливания и поглъщания

BBVA Won't Withdraw Sabadell Offer

30.06.2025 г., 23:43 ч. UTC

Пазарно говорене

Gold Edges Higher, Underpinned by Fed-Rate Cut Hopes -- Market Talk

30.06.2025 г., 23:38 ч. UTC

Пазарно говорене

Nikkei May Fall as Yen Has Strengthened Amid Trade Uncertainty -- Market Talk

30.06.2025 г., 23:38 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

30.06.2025 г., 23:03 ч. UTC

Печалби

Boeing CFO Exit Is Latest Change in Chief Executive Kelly Ortberg's C-Suite -- Update

30.06.2025 г., 22:50 ч. UTC

Придобивния, сливания и поглъщания

Giant Eagle Closes Sale of Its GetGo Business to Alimentation Couche-Tard

30.06.2025 г., 22:50 ч. UTC

Печалби

Boeing Hires Former Lockheed Martin Executive to Succeed CFO Brian West -- Update

30.06.2025 г., 21:26 ч. UTC

Печалби

Berkshire Stock Ends Quarter on Sour Note. It's About Even With S&P 500 So Far in 2025. -- Barrons.com

30.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

30.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

30.06.2025 г., 19:46 ч. UTC

Пазарно говорене

Nike's Buzz is Back Amid Lean into Women Sports -- Market Talk

30.06.2025 г., 19:16 ч. UTC

Пазарно говорене

Oil Futures Snap Winning Streak on OPEC+ Outlook -- Market Talk

30.06.2025 г., 19:10 ч. UTC

Пазарно говорене

U.S. Natural Gas Wipes Out Friday's Gains -- Market Talk

30.06.2025 г., 19:07 ч. UTC

Пазарно говорене

Dollar Ends Losing Quarter Facing Downward Pressure -- Market Talk

30.06.2025 г., 18:27 ч. UTC

Пазарно говорене

Gold Has Largest Half-Year Gain Since 2007 -- Market Talk

30.06.2025 г., 17:08 ч. UTC

Придобивния, сливания и поглъщания

MicroStrategy Stock Jumps After Latest Bitcoin Purchase as Holdings Near 600,000 Tokens -- Barrons.com

30.06.2025 г., 17:00 ч. UTC

Придобивния, сливания и поглъщания

HPE Stock Soars as Juniper Merger Gets Regulatory Approval. There's Just 1 Catch. -- Barrons.com

30.06.2025 г., 16:41 ч. UTC

Пазарно говорене

WTI Crude Undeperforms as U.S.-Canada Trade Talks to Resume -- Market Talk

30.06.2025 г., 16:32 ч. UTC

Пазарно говорене

United Parks' Potential Buyback Resumption Could Be Catalyst For Stock -- Market Talk

30.06.2025 г., 16:23 ч. UTC

Придобивния, сливания и поглъщания

BBVA: Offer Remains in Effect in Accordance With Applicable Regulations

30.06.2025 г., 16:22 ч. UTC

Придобивния, сливания и поглъщания

BBVA Decided Not to Withdraw Offer for Banco De Sabadell

30.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

30.06.2025 г., 16:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

30.06.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

30.06.2025 г., 16:07 ч. UTC

Печалби

Umicore to Post 1H Results on Aug 1

30.06.2025 г., 15:59 ч. UTC

Пазарно говорене

Copper Conditions Set to Remain Tight But Risks Loom -- Market Talk

30.06.2025 г., 15:55 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Home Depot to Consolidate Pro Distribution with GMS Deal -- Market Talk

30.06.2025 г., 15:54 ч. UTC

Пазарно говорене

Gold Futures Recoup Some Losses Though Demand Looks Set to Weaken -- Market Talk

30.06.2025 г., 15:41 ч. UTC

Придобивния, сливания и поглъщания

Google Bets Big on Nuclear Fusion With MIT Spinoff Commonwealth -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Erasca Inc Прогноза

Ценова цел

By TipRanks

224.43% нагоре

12-месечна прогноза

Среден 4.25 USD  224.43%

Висок 6 USD

Нисък 3 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Erasca Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

4

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

1.39 / 1.44Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Weak Bearish Evidence

Дългосрочен план

Very Strong Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.